tbuckley/cabot-search huggingface dataset:
Follicular Thyroid Adenoma Showing Avid Uptake on 68Ga-DOTA-FAPI-04 PET/CT
Authors: Lei Ou, Junhao Wu, Ji Wu, Chunru Mou, Chunyin Zhang
Journal: Clinical Nuclear Medicine (2021)

We describe the case of a 48-year-old man suspected to have recurrent colon carcinoma who underwent 68Ga-DOTA-FAPI-04 PET/CT, revealing the presence of an incidentaloma with intense FAPI uptake in the left thyroid lobe. Based on PET/CT findings, malignancy was suspected. Biopsy confirmed the diagnosis of follicular thyroid adenoma with fibrosis and calcification. This case emphasizes the need to increase awareness of this benign lesion in the differential diagnosis of incidental thyroid nodules with high FAPI activity.
Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial
Authors: Jawad Fares, Atique U Ahmed, Ilya V Ulasov, Adam M Sonabend, Jason Miska, Catalina Lee-Chang, Irina V Balyasnikova, James P Chandler, Jana Portnow, Matthew C Tate, Priya Kumthekar, Rimas V Lukas, Sean A Grimm, Ann K Adams, Charles D Hébert, Theresa V Strong, Christina Amidei, Victor A Arrieta, Markella Zannikou, Craig Horbinski, Hui Zhang, Kirsten Bell Burdett, David T Curiel, Sean Sachdev, Karen S Aboody, Roger Stupp, Maciej S Lesniak
Journal: The Lancet Oncology (2021)
Abstract 436: Mfn2 is a Nodal Point Regulatory Step That Coordinates Angiogenic Phenotype in the Vascular Endothelium
Authors: Gladys A Nchaw, Kyriakos N Papanicolaou, Jennifer L Parker-Duffen, Ramon G Bonegio, Kenneth Walsh
Journal: Circulation Research (2016)

Recent published data suggests that endothelial metabolism regulates angiogenesis. The key regulators of mitochondrial dynamics, mitofusins (Mfn1 and Mfn2) have been linked to cellular metabolic profile in tissues with high energetic requirements but their role in endothelial cells, were mitochondria function as signaling organelles is unknown. Here, we found that Mfn2 modulates postnatal neovascularization. Endothelial deletion of Mfn2 (Mfn2 ecko ) impaired, whereas, endothelial Mfn1 deletion (Mfn1 ecko ) did not affect clinical recovery, limb blood flow reperfusion, and capillary density compared with wild-type mice. These effects were associated with reduced eNOS activation in the ischemic leg of Mfn2 ecko mice compared with wild-type mice. Transplantation of bone marrow cells from WT to Mfn2ecko mice did not significantly improve blood perfusion in the ischemic limb of Mfn2 ecko mice. In agreement with these results, salient features of angiogenesis such as eNOS phosphorylation, cell migration, proliferation and capillary sprout formation were significantly inhibited in Mfn2 null primary mouse lung endothelial cells (Mfn2 -/- MLECs), whereas ablation of Mfn1 did not affect angiogenic signaling following VEGF stimulation. Because Mfn2 modulates the unfolded protein response (UPR) and the UPR machinery has been shown to generate angiomodulatory signals, we ascertained the effects of Mfn2 loss on UPR-mediated VEGF angiogenic signal transduction as potential mechanism. Mfn2 ablation sensitized Mfn2 -/- MLECs to proapototic UPR activation following VEGF treatment according to CHOP levels. Augmented CHOP levels corresponded with reduced eNOS phosphorylation. Inhibition of the UPR PERK signaling axis with PERK siRNA or reconstitution of Mfn2 (AdMfn2) reduced CHOP levels and significantly improved eNOS activation, EC proliferation and migration in Mfn2 -/- MLECs. Moreover, PERK siRNA or reconstitution of Mfn2 rescued the defect in capillary sprout formation in Mfn2 ecko mice. These data suggest that Mfn2 regulate angiogenic signaling in a UPR PERK axis-dependent manner and extend the role of Mfn2 beyond mitochondrial dynamics, metabolism and ER stress to angiogenesis and reparative vascular remodeling.
Aldehyde Dehydrogenase 2 (ALDH2) Expression Predicts a Poor Prognosis in Acute Myeloid Leukemia
Authors: Linus Angenendt, Eike Bormann, Jan-Henrik Mikesch, Tobias Herold, Klaus H. Metzeler, Stefan K. Bohlander, Dennis Görlich, Maria Francisca Arteaga, Bernhard J. Wörmann, Georg Lenz, Wolfgang Hiddemann, Karsten Spiekermann, Utz Krug, Christina Sauerland, Wolfgang E. Berdel, Christoph Schliemann
Journal: Blood (2017)
ラットにおける実験的メサンギウム増殖腎炎の進行を防止するアンギオテンシンII(ANG.II)遮断
Authors: Nakamura T, Kimura H, Obata J, Ikeda Y, Kuroyanagi R, Kawachi H, Shimizu F
Journal: Journal of the American Society of Nephrology (1995)
Post-Allogeneic Stem Cell Transplant Surveillance of CD34+ Sorted Peripheral Blood to Quantify Emergent DNMT3A, IDH and NPM1 clones and Correlation with Clinical Outcome
Authors: Shaun Fleming, Nik Cummings, Tongted Das, Adam Ivey, Julie McManus, Sharon Avery, Sushrut S. Patil, Patricia A. Walker, David J. Curtis, Andrew Spencer, Andrew Wei
Journal: Blood (2017)
Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response
Authors: Fredrik N Albach, Gerd R Burmester, Robert Biesen
Journal: Annals of the Rheumatic Diseases (2021)

The COVID-19 pandemic poses unique challenges regarding the optimal care of patients with rheumatic diseases, who may have an increased risk of infection and hospitalisation. It is therefore highly important to ensure successful vaccination of these patients.1 The messenger RNA vaccine BNT162b2 (Comirnaty by BioNTech/Pfizer) against SARS-CoV-2 strongly reduces infection, transmission, hospitalisation and death in immunocompetent patients. The development of neutralising antibodies after vaccination has been associated with protection from COVID-19.2 However, a decreased immunogenicity of several vaccines has been described under immunosuppressive medication,3 and first reports seem to confirm reduced antibody responses after vaccinations against SARS-CoV-2 in patients on some immunosuppressive medications (e.g. in one preprint rituximab, glucocorticoids and possibly JAK inhibitors).4 This led rheumatologists to address the question of how to deal with patients who show insufficient immunogenicity after vaccination.

In this letter, we describe a case with an initially negative antibody response and seroconversion after repeated booster vaccinations without interruption of immunosuppressive medication. The patient is a 54-year-old man, …
Identification of multiple novel prostate cancer susceptibility loci by a genome-wide association study
Authors: Rosalind Eeles, Zsofia Kote-Jarai, Graham Giles, Ali Al Olama, Michelle Guy, Stephen Edwards, Shani Mulholland, Sarah Jugurnauth, Daniel Leongamornlert, Malgorzata Tymrakiewicz, Sameer Jhavar, David Dearnaley, Jonathan Morrison, Helen Field, Melissa Southey, Gianluca Severi, Jennifer Donovan, Freddie Hamdy, Kenneth Muir, Colin Cooper, Dallas English, John Hopper, David Neal, Douglas Easton
Journal: Cancer Research (2008)

5810  Prostate cancer (PrCa) is the commonest cancer in developed countries. It exhibits consistent evidence of familial aggregation, but the causes of this aggregation are mostly unknown. To identify common PrCa susceptibilility alleles, we conducted a genome-wide association study using 1,854 PrCa cases with clinically detected prostate cancer diagnosed at
The Significance of J Wave in Acute Myocardial Infarction
Authors: Seya Mie, Nishizaki Mitsuhiro, Kida Natsuko, Inamura Yukihiro, Nakamura Tomofumi, Takayama Kei, Shimizu Masato, Fujii Hiroyuki, Yamawake Noriyoshi, Isobe Mitsuaki
Journal: Circulation (2013)
Photo-responsive hydrogel facilitates nutrition deprivation by an ambidextrous approach for preventing cancer recurrence and metastasis
Authors: Hao Wang, Yi Jin, Yanli Tan, Han Zhu, Wendi Huo, Pei Niu, Zhenhua Li, Jinchao Zhang, Xing-jie Liang, Xinjian Yang
Journal: Biomaterials (2021)
Abstract 398: Alternative Splicing of Titin Restores Diastolic Function and Improves HFpEF Associated Symptoms
Authors: Mathew Bull, Mei Methawasin, Joshua Strom, Pooja Nair, Kirk Hutchinson, Henk Granzier
Journal: Circulation Research (2016)

Greater than half of all heart failure (HF) patients suffer from increased diastolic stiffness and impaired relaxation of the left ventricle while their ejection fraction (EF) is preserved (HFpEF). HFpEF is a complex disease characterized by diastolic dysfunction, exercise intolerance, and concentric hypertrophic remodeling. No effective therapy exists for treating this pervasive disease due in part to our limited understanding of the underlying pathophysiology. Titin, the largest known protein and molecular spring in the heart, has emerged as a prime candidate for therapeutic targets aimed at restoring compliance to the sarcomere in order to improve diastolic function. Titin has two main cardiac isoforms; the smaller N2B isoform (~3.0 MDa) and the larger more compliant N2BA isoform (~3.3 MDa). Diastolic stiffness of the left ventricle is in large part dependent upon the N2BA:N2B isoform ratio. Modification of these two primary isoforms can be achieved post-transcriptionally through inhibiting the known titin splicing factor Rbm20. Alternative splicing of messenger RNA occurs primarily in the spring region of titin and therefore regulates the elastic property of titin through changes in contour length of the spring. The current study evaluates whether reduction of titin splicing factor Rbm20 has a beneficial effect on the diastolic function of mice with restrictive cardiomyopathy. A previously published mouse model deficient in titin’s IA junction ( Ttn ΔIAjxn ) places increased strain on the spring region of titin and acts as a mechanical analogue of the titin-based increase in passive myocardial stiffness found in HFpEF patients. This model exhibits a HFpEF-like phenotype apparent as early as 3 months in the adult mouse that becomes exaggerated with age apart from pharmacological or surgical intervention. We report for the first time a rescue of HFpEF in the mouse through inhibiting Rbm20. We demonstrate that Rbm20 reduction restores diastolic function, improves exercise tolerance and attenuates afterload induced pathologic remodeling of the left ventricle. No specific FDA approved therapies exist to treat the pathologically stiff left ventricle, therefore our findings on Rbm20 inhibition are clinically significant.
Endoscopic removal of an entirely embedded esophageal fishbone
Authors: Wei Liu, Long He, Xiang-Lei Yuan, Bing Hu
Journal: Endoscopy (2021)

A 65-year-old man was referred to our hospital with a 3-day history of pain in the upper esophagus after eating fish. Subsequent computed tomography (CT) showed a fishbone in the upper esophagus without any injury to the surrounding vessels. Emergency endoscopy was performed under general anesthesia. During the procedure, we tried to remove the fishbone with biopsy forceps through a high-definition gastroscope (GIF-Q260J; Olympus, Tokyo, Japan). However, only congestion and edema of the local esophagus were confirmed and the fishbone could not be found ([Fig. 1 a]), suggesting that it had become entirely embedded in the esophageal wall. Further evaluation of the location of the fishbone was completed based on the endoscopic findings, CT scan, and three-dimensional image reconstruction ([Fig. 2]). After full communication with the patient, a second try was made ([Video 1]). In this process, a hook knife was used to create an incision ([Fig. 1 b]) and the fishbone was partially exposed ([Fig. 1 c]). Next, the 3-cm-long fishbone was successfully extracted using grasping forceps ([Fig.1 d, f]), without closing the esophageal incision ([Fig. 1 e]). The whole endoscopic procedure only took about 10 minutes as an outpatient procedure; the patient was discharged immediately and was allowed a liquid diet 6 hours after treatment. The operative and postoperative periods were uneventful, without any complications.
Suppressor of cytokine signalling-2 controls hepatic gluconeogenesis and hyperglycemia by modulating JAK2/STAT5 signalling pathway
Authors: Xu Zhang, Yuan Zhuang, Tian Qin, Meijia Chang, Xuetao Ji, Ning Wang, Zhilei Zhang, Hongwen Zhou, Qian Wang, John Zhong Li
Journal: Metabolism (2021)
A cyclodextrin-based nanoformulation achieves co-delivery of ginsenoside Rg3 and quercetin for chemo-immunotherapy in colorectal cancer
Authors: Dandan Sun, Yifang Zou, Liu Song, Shulan Han, Hao Yang, Di Chu, Yun Dai, Jie Ma, Caitriona M. O'Driscoll, Zhuo Yu, Jianfeng Guo
Journal: Acta Pharmaceutica Sinica B (2021)

The immune checkpoint blockade therapy has profoundly revolutionized the field of cancer immunotherapy. However, despite great promise for a variety of cancers, the efficacy of immune checkpoint inhibitors is still low in colorectal cancer (CRC). This is mainly due to the immunosuppressive feature of the tumor microenvironment (TME). Emerging evidence reveals that certain chemotherapeutic drugs induce immunogenic cell death (ICD), demonstrating great potential for remodeling the immunosuppressive TME. In this study, the potential of ginsenoside Rg3 (Rg3) as an ICD inducer against CRC cells was confirmed using
Abstract 137: Ctcf is Essential for Transcriptome Regulation in the Healthy Heart
Authors: Manuel Rosa-Garrido, Todd Kimball, Douglas J Chapski, Tsai-Ting Shih, Elizabeth Soehalim, Enrique Balderas, Niels J Galjart, Yibin Wang, Thomas M Vondriska
Journal: Circulation Research (2016)

Heart failure is a syndrome resulting from complex genetic predisposition and multiple environmental factors. It is well established that global changes in gene expression accompany the transition through hypertrophy and on to overt failure producing deterioration of function at the organ level. Unknown, however, are the global changes in chromatin structure that allows for pathological gene expression. The epigenetic factor CTCF is a ubiquitous protein thought to be involved in maintenance of chromatin microenvironments. We found that hypertrophic stimulation down-regulates CTCF in the heart, and CTCF expression is significantly correlated with heart size in disease across genetic backgrounds. To test this relationship further, we have generated an inducible cardiac-specific CTCF knockout animal. These animals quickly develop severe heart failure characterized by a dilated left ventricle, decreased ejection fraction, and reactivation of the fetal gene program. Our analysis of published CTCF ChIP-seq data performed in mouse heart has also shown CTCF binding peaks flanking the fetal genes. Furthermore, we have found that CTCF abundance at these sites changes after hypertrophic agonist isoproterenol treatment, suggesting that CTCF protects from the development of cardiac disease by regulating gene expression. We also used RNA-seq to compare the transcriptome of adult myocytes isolated from control, CTCF KO mice, and mice that underwent transverse aortic constriction (TAC) to induce heart failure. These analyses showed that CTCF depletion remodels gene expression in a manner that mimics aspects of the pathological transcriptome in heart failure. Our data demonstrate that precise control of CTCF levels is required for normal transcriptome regulation in the adult heart and that alterations in CTCF levels (either via genetic, pharmacologic or surgical techniques) lead to cardiac pathology.
First-Line Dasatinib in BCR-ABL1+ Chronic Myeloid Leukemia in Early Chronic Phase: A Gimema Prospective Multicentric Observational Study
Authors: Fausto Castagnetti, Gabriele Gugliotta, Massimo Breccia, Federica Sorà, Alessandra Iurlo, Antonella Gozzini, Anna Rita Scortechini, Luigia Luciano, Fabio Stagno, Alessandra Malato, Elisabetta Abruzzese, Monica Crugnola, Patrizia Pregno, Giorgina Specchia, Pellegrino Musto, Nicola Cascavilla, Mario Tiribelli, Massimiliano Bonifacio, Piero Galieni, Fausto Palmieri, Simona Soverini, Maria Teresa Bochicchio, Simona Sica, Robin Foà, Michele Cavo, Giovanni Martinelli, Giuseppe Saglio, Fabrizio Pane, Michele Baccarani, Gianantonio Rosti
Journal: Blood (2017)
A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression
Authors: Zhenggang Ren, Shukui Qin, Zhiqiang Meng, Zhendong Chen, Xiaoli Chai, Jianping Xiong, Yuxian Bai, Lin Yang, Hong Zhu, Weijia Fang, Xiaoyan Lin, Xiaoming Chen, Enxiao Li, Linna Wang, Ping Yan, Jianjun Zou
Journal: Liver Cancer (2021)

In a multicenter, open-label, parallel-group, randomized, phase 2 study for pretreated advanced hepatocellular carcinoma (HCC), camrelizumab showed potent antitumor activity and acceptable safety profile. The aim of this report was to provide long-term data and evaluate potential benefit of treatment with camrelizumab beyond progression.From November 15, 2016, to November 16, 2017, 217 patients received camrelizumab 3 mg/kg intravenously every 2 or 3 weeks. Treatment beyond first Response Evaluation Criteria in Solid Tumors (RECIST)-defined progression (TBP) with camrelizumab was allowed.At data cutoff of December 16, 2019 (>2 years after the last patient enrollment; median duration of follow-up, 13.2 months [IQR 5.7-25.8]), 14 (43.8%) of the 32 responses per blinded independent central review were ongoing. The median duration of response was not reached (range 2.5-30.5 + months). The ongoing response rates at 12, 18, and 24 months were 68.3% (95% confidence interval [CI] 47.7-82.2), 59.8% (95% CI 38.8-75.6), and 53.1% (95% CI 31.0-71.0), respectively. The median overall survival (OS) was 14.2 months (95% CI 11.5-16.3). The 18- and 24-month OS rates were 41.3% (95% CI 34.6-47.9) and 33.7% (95% CI 27.3-40.2), respectively. Of the 172 patients who experienced RECIST-defined progression per investigator, 102 received TBP, while 70 did not (non-TBP). The median OS was 16.9 months (95% CI 13.3-22.6) in the TBP group versus 9.4 months (95% CI 5.8-14.8) in the non-TBP group, and the 18- and 24-month OS rates were 47.5% (95% CI 37.3-56.9) versus 33.1% (95% CI 22.3-44.3) and 38.8% (95% CI 29.2-48.4) versus 23.2% (95% CI 13.8-34.1), respectively. No new safety signals of camrelizumab were observed.With prolonged follow-up, camrelizumab continues to demonstrate the durable response and long survival in pretreated advanced HCC patients with manageable toxicities, especially in those who continued the treatment beyond first RECIST-defined progression.
Abstract 431: Initial Nutrition Status is Associated With Neurologic Outcome in Post Cardiac Arrest Patients
Authors: Sumin Cho, Eunjung Park, Sungeun Lee, Minjung K Chae
Journal: Circulation (2019)

Background: Poor nutrition is associated with mortality in critically ill patients. Also overweight BMI, low albumin is known to be associated with poor neurologic outcome in post cardiac arrest patients. We aimed to assess the association between initial nutritional status and poor neurologic outcome in post cardiac arrest patients. Methods: The nutrition support team(NST) initially assesse all patients admitted to the ICU in 24 hours of admission. All patients are screened for initial nutrition status with age, height, weight, laboratory results, signs of poor nutrition, nutrition risk comorbidities into consideration. We retrospectively analyzed the nutrition risk from the initial nutrition risk record assessed by NST and compared the nutrition risk between outcome groups. Furthermore, we did a multivariate logistic regression correcting for confounding variables to investigate the association between the initial nutrition risk and neurologic outcome. Results: High nutrition risk was associated with poor neurologic outcome (OR 3.03 [1.25-7.33], p=0.01) compared to the low nutritional risk group after adjusting for age, sex, CPR duration and initial shockable rhythm. Conclusion: High initial nutrition risk was associated with poor neurologic outcomes in our study.
Vitamin D Relation to Busulphan in Pediatrics Undergoing Hematopoietic Stem Cell Transplantation
Authors: Fadwa Benkessou, Moustapha Hassan, Ibrahim El serafi, Ahmed El serafi, Wenyi Zheng, Manuchehr Abedi-Valugerdi, Jonas Mattsson, Martin Höglund, Karin Mellgren
Journal: Blood (2017)
Abstract 125: Automated External Defibrillator Shock Advisement Performance Among Multiple Human Electrocardiographic Rhythms and Devices
Authors: Xavier J Szigethy, Connor J Willson, David D Salcido, Dylan A Defilippi, James J Menegazzi
Journal: Circulation (2019)

Background: Automated external defibrillators (AEDs) perform rhythm analysis in order to facilitate defibrillation. The effectiveness of AEDs is dependent on the accuracy of their rhythm classification, which includes differentiation of shockable rhythms from non-shockable rhythms Independent (i.e. non-industry) evaluation of the performance of AEDs against real-world ECG could lead to improvements in their performance. Objective: To evaluate the sensitivity and specificity characteristics of commercial AEDs with respect to quantitative properties of the ECG waveform in several rhythm presentations using real world ECG data. Methods: We conducted a prospective simulation study evaluating three commercially available AEDs from Defibtech, Phillips, and Zoll on the determination of ECG rhythm shockability. Performance was evaluated for 181 human ECG recordings (101 ventricular fibrillation-VF, 55 PEA, and 25 asystole) ranging widely in signal characteristics, obtained from the Pittsburgh site of the Resuscitation Outcomes Consortium. We used a commercially available digital-to-analog converter (National Instruments USB-6001) to inject the recordings into each AED through a direct lead-wire interface, recording shock advisement decisions in a best-out-of-three approach for each device/rhythm pairing. We calculated the sensitivity and specificity for discriminating VF and non-VF rhythms for each device and overall. VF signal characteristics were calculated, including peak frequency, median amplitude, and peak amplitude, and the VF quantitative waveform measures AMSA and median slope. Results: The 101 VF trials featured signals with mean peak frequency 10.02 Hz(IQR 4.80 Hz), mean AMSA 9.13(IQR 7.29), mean median slope 6.72 (IQR 3.66). The sensitivities were: Defibtech 99.0%; Philips 97.0%; Zoll 98.0%. The specificities were: Defibtech 98.7%; Philips 96.2%; Zoll 97.4%. Defibtech recorded 5 discordant advisements and Philips and Zoll recorded eight each. The overall sensitivity was 98.0%, and the specificity 97.4%. Conclusion: Evaluated against a wide variety of real-world signal presentations, commercial AEDs demonstrated a high degree of sensitivity and specificity for shockable ECG rhythms.
ヒト褐色脂肪細胞熱発生はβ_2-AR刺激により駆動される【JST・京大機械翻訳】
Authors: P Blondin Denis, Nielsen Soren, N Kuipers Eline, C Severinsen Mai, H Jensen Verena, Miard Stephanie, Z Jespersen Naja, Kooijman Sander, R Boon Marieette, Fortin Melanie, Phoenix Serge, Frisch Frederique, Guerin Brigitte, E Turcotte Eric, Haman Francois, Richard Denis, Picard Frederic, C N Rensen Patrick, Scheele Camilla, C Carpentier Andre
Journal: Cell Metabolism (2020)
Absence of T1 Hyperintensity in the Brain of Thalassemia Patients after Multiple Administrations of Gadobutrol
Authors: Antonella Meloni, Domenico Montanaro, Daniele De Marchi, Maria Chiara Resta, Petra Keilberg, Laura Pistoia, Anna Spasiano, Tommaso Casini, Caterina Cinzia De Bari, Sara De Cori, Vincenzo Positano, Paolo Di Bartolomeo, Alessia Pepe
Journal: Blood (2017)
Abstract 15511: Long-Term Effect of Bariatric Surgery on the Incidence and Outcomes of Obesity-Related Peripheral Vascular Disease
Authors: Osama Moussa, Maddalena Ardissino, Silvia Muttoni, Ara Faraj, Alice Tang, Paul Ziprin, Ara Darzi, Omar Khan, Peter Collins, Usman Jaffer, Sanjay Purkayastha
Journal: Circulation (2019)

Background: Patients with obesity are at high risk of suffering from both arterial and venous peripheral vascular disease. Bariatric surgery is an effective and increasingly popular strategy to ach...